# Matthew Guldin

Matthew Guldin writes about healthcare technology and reviews conference proposals, including for the HIMSS Global Health Conference. Guldin's posts focus on how to show the real-world impact of technology: the problem it addressed, what changed, measurable results, and lessons other healthcare organizations can use.

- Profile: https://b2binfluencer.marketing/creators/matthew-guldin/
- LinkedIn: https://www.linkedin.com/in/mattguldin
- LinkedIn followers: 6,346
- Topics: healthcare
- Based on 12 dated posts, latest 2026-08-31

## Summary

Useful for sharpening healthcare technology case studies and HIMSS conference proposals around measurable impact.

- Best for: Healthcare IT consultancies and teams preparing HIMSS submissions or implementation case studies.
- Not for: Reach-led consumer health or medical device brand awareness campaigns.
- Check first: Confirm audience demographics, engagement data, and whether they offer sponsorship or partnership terms.

### Takeaways

- Implementation is not an outcome; impact is.
- Proposals should show baseline, credible results, and lessons learned.
- Case studies should explain clinician pushback or a metric that failed to move.

## Main ideas

- **Implementation is not an outcome; impact is**: Guldin reviews proposals for the HIMSS Global Health Conference and says the ones that hold attention are rarely about the newest technology. They make clear what changed. A proposal should start with a specific problem, not "we implemented AI" or "we built an interoperability platform," explain who was affected and what things looked like beforehand, then report results tied to that starting point. HIMSS explicitly asks reviewers to look for completed results, KPIs, or outcomes. The numbers need not be spectacular, just credible and connected to the original problem. Guldin also checks that the title, abstract, learning objectives, and content tell one story rather than promising one thing and delivering another.
- **Don't let a provider-vendor case study become a product pitch**: Both HIMSS posts return to submissions that pair a health system with a vendor. Guldin says the vendor need not disappear and the technology matters, but the product should not be the story. The audience should hear about the healthcare problem, the decisions made, what changed, the results, and what they can take back to their own organization. HIMSS is explicit about commercial bias. Guldin adds a practical reason: reviewers do not need to hear how good a platform is, only why the organization chose that approach, how it was implemented, what happened, and whether the lessons travel.
- **The most useful proposals admit what didn't work**: Guldin says some of the most useful proposals they have reviewed explain what went wrong. Healthcare technology implementations are rarely as clean as the final case study makes them look. Guldin wants concrete answers: Where did the team underestimate the difficulty? What did clinicians push back on? Which metric did not move? What had to change halfway through? The final test is transferability: whether someone else can use what was learned as a governance model, measurement approach, process, decision framework, or simply three things the team would do differently if starting over.
- **Healthcare market change comes through structures, not one business model**: Away from proposal mechanics, Guldin covers the convergence of nonprofit health systems, private equity investors, and for-profit operators. They summarize a Private Equity Stakeholder Project report on joint ventures between private equity-backed companies and nonprofit health systems and explain why both sides participate: health systems under financial and operational pressure gain capital, expertise, and infrastructure without carrying the full cost and risk, while private equity firms gain access to established networks, brands, and patient populations. Guldin raises questions about transparency in complex ownership structures, who controls strategic and operational decisions, how incentives are aligned, and whether regulatory oversight has kept pace. Their conclusion: transformation happens through acquisitions, partnerships, affiliations, outsourcing, and joint ventures, not through any single model.
- **Put practitioners' measurable work on the agenda**: Guldin promotes conference speaking as a way to spread practical solutions. Announcing the call for presentations for the 2026 NJDVHIMSS Annual Conference in Atlantic City, they invite people who have improved patient care, streamlined operations, reduced clinician burden, or used technology in a meaningful way to submit. They single out sessions that go beyond theory to show measurable outcomes, lessons learned, and practical approaches others can adapt. The invitation spans health systems, payers, government agencies, startups, consulting firms, and technology companies, matching the cross-sector audience Guldin writes for elsewhere.

## Work to read

- [What makes a HIMSS proposal compelling: baseline, credible results, and lessons learned](https://www.linkedin.com/posts/mattguldin_healthit-himss27-digitalhealth-activity-7497724913672228864-XxVv)
- [How to tell the story behind a health IT implementation](https://www.linkedin.com/posts/mattguldin_healthit-himss27-digitalhealth-activity-7500329805817479168-KuXB)
- [Call for presentations for the 2026 NJDVHIMSS Annual Conference](https://www.linkedin.com/posts/mattguldin_one-of-the-best-parts-of-attending-healthcare-activity-7484755196556943360-wmPF)
- [Private equity’s growing joint ventures with nonprofit health systems](https://www.linkedin.com/posts/mattguldin_private-equity-investment-in-healthcare-isn-activity-7481457216340983808-N3IA)

## Brand relationships

- **HIMSS** (affiliate)
- **NJDVHIMSS** (mention)
- **Private Equity Stakeholder Project** (mention)

## Partnerships

Matthew Guldin's posts do not describe a sponsorship or partnership offering. The four posts are commentary, not commercial terms. Two discuss healthcare partnership structures: joint ventures between private equity-backed companies and nonprofit health systems, and provider-vendor conference presentations. The other two cover HIMSS conference proposal reviews and a regional HIMSS call for presentations, inviting healthcare organizations to submit speaking proposals—not sponsors to buy placement. Guldin publishes no formats, deliverables or pricing in these posts. Ask directly what they offer; the posts provide no inquiry channel for commercial partnerships.

## Alternatives

- Charles J. French: Choose French when the consultancy's work is on the vendor side of a provider-vendor story, rather than reviewing somebody else's abstract. In two posts, they make the move they recommend: open with the clinician — nurses pulled off bedside care by nuisance calls — then translate that into measures a hospital executive owns, naming HCAHPS quietness and staff responsiveness and the share of value-based purchasing payments at risk, before introducing the product. That ordering, and the judgment about how far down a post a brand name can sit, are directly useful when a consultancy client is a supplier that keeps writing its case study as a product pitch.
- Suleman Adil: Adil is the closer substitute when a consultancy client faces a commercial rather than editorial problem: a health-tech supplier has secured pilots or framework places but cannot show the technology is used, renewed, or changing care. The August 2026 posts extend the line in Guldin's "implementation isn't an outcome" into the market: an implementation count shows a supplier got access to a trust, not that clinicians kept using the technology, documentation time fell, or the contract will scale. A large footprint can also hide a weakening base when customer success, onboarding, support, or integrations are stretched. Adil documents a first step a buyer can act on: a free opening conversation described as a candid review of commercial model, customer journey, retention risk, and go-to-market strategy.
- John C.: Consider John C. when the consultancy's objective shifts from submission quality to how health-system technology leaders build careers and boards — for programming aimed at CIOs or content for an executive-audience brief. The posts address that audience on its own terms: what a board actually asks about strategy, risk, financial viability, and the leadership pipeline; why a nonprofit or advisory board seat is worth taking before the first corporate board; and why a CIO needs current cyber-risk knowledge across connected medical devices, identity and access, Zero Trust, ransomware resilience, incident recovery, and AI-enabled threats that keep that knowledge from staying current. For a leadership-development or executive-education campaign, this vocabulary sits closer to the buying audience than a conference proposal checklist does.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/